Below is a list of current clinical trials open to enrollment at New England Cancer Specialists. Trials can open and close very quickly, depending on the phase of the study, responses from patients already enrolled, or FDA requests.
We try to have a trial available in every disease area, but this isn’t always possible. If you don’t see a study that might be right for you, please ask your doctor or nurse.
For a full list of clinical trials across the U.S., visit www.clinicaltrials.gov.
Bladder, S1314 (SWOG)
A randomized Phase II Study of Co-Expression Extrapolation (Coxen) With Neoadjuvant Chemotherapy For Localized, Muscle-Invasive Bladder Cancer.
Bladder, T-3-15 (W029636/IMvigor 010)
A Phase III, Open-Label, Multicenter, Randomized, Study of Atezolizumab (Anti-PD-L1 Antibody) vs. Observation as Adjuvant Therapy in Patients with PD-L1-Selected, High –Risk Muscle-Invasive Bladder Cancer after Cystectomy
Bladder, T-6-16 (MK3475-361-00) A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced of Metastatic Urothelial Carcinoma.
Brain, Alliance A071102 (Temporarily closed to accrual)
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
Brain EV-2-16 (OT-15-001) STELLAR
A Phase III, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy.
Breast, CB-1-15 (CP-MGAH22-04/SOPHIA)
A Phase III, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in Treatment in Patients with HER2+ MBC Who Have Received Two Prior anti-Her2 Therapies and Require Systemic Treatment
Breast, CB-2-15, Alliance Foundation (AFT-05/PALLAS)
Breast, CB-2-15, Alliance Foundation (AFT-05/PALLAS): Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
Breast, W-1-16 (PTL-10140)
A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna in Early Stage Breast Cancer Patients Who Are Candidates for Genomic Testing
Breast, CB-1-16 (C31006-TRIO)An Open-Label Phase II Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During of After Aromatase Inhibitor Therapy. MLN0128 in Combination with Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy.
Colorectal, NSABP C-13/ARGO
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Gastric, DU-4-15 (GS-US-296-1080A)
Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Genomics, EAY 131 (ECOG-ACRIN)
Molecular Analysis for Therapy Choice (MATCH)
Leukemia, R-1-16 (informCLL)
A disease registry for patients with Chronic Lymphocytic Leukemia
Lung, T-1-16 (SOLAR)
An Open-Label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in 1st-Line Treatment of Patients with Stage IIIB/IV NSCLC Tumors with EGFR Activating Mutations
Lung, T-2-15 (GO29437)
A Phase III, Open-Label, Multicenter, Randomized Study evaluating the efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel Or MPDL3280A In Combination With Carboplatin + NAB Paclitaxel Versus Carboplatin + NAB-Paclitaxel In Chemotherapy Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer
Lung, T-3-16 (CheckMate 370)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and NivoluMAb Clinical Trial Evaluation 370)
Lung, T-4-15 (GO29527/IMpower 010)
A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1-Selected Patients with Completely Resected Stage IB-IIIA NSCLC
Lung, T-4-16 (GO30081/IMpower133))
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
Lung, Alliance A081105
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Lung, Alliance A151216
Adjuvent Lung Cancer Enrichment Marker Identification and Sequencing
Lung, ECOG E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (part of ALCHEMIST study).
Randomized Phase II/III Study of (Nivolumab + Ipilimumab + Sargramostom) vs (Niolumab + Ipilimumab) in Patients with Unresectable Stage III or Stage IV Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Registry - All Cancers, R-3-12 (M07-001) Alexion Pharmaceuticals
PNH Registry (Paroxysmal Nocturnal Hemoglobinuria)
Renal, T-2-16 (JAVELIN Renal 101)
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab (MSB0010718C) In Combination With Axitinib Versus Sunitinib Monotherapy In The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma